tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

MNMD Stock Latest News

Psychedelic: Clearmind completes second cohort treatment for CMND-100 trial
The FlyPsychedelic: Clearmind completes second cohort treatment for CMND-100 trial
1d ago
PBM
CMND
Five new option listings and one option delisting on January 15th
PremiumThe Fly
Five new option listings and one option delisting on January 15th
1d ago
MNMD
Definium Therapeutics: De-Risked Late-Stage Neuropsychiatric Pipeline Positions 2026 as Catalyst-Rich Year Supporting Buy Rating and $32 Target
PremiumRatings
Definium Therapeutics: De-Risked Late-Stage Neuropsychiatric Pipeline Positions 2026 as Catalyst-Rich Year Supporting Buy Rating and $32 Target
4d ago
MNMD
Definium Therapeutics Rebrands and Highlights 2026 Pipeline
PremiumCompany Announcements
Definium Therapeutics Rebrands and Highlights 2026 Pipeline
4d ago
8K
MNMD
Mind Medicine rebrands to Definium Therapeutics
PremiumThe Fly
Mind Medicine rebrands to Definium Therapeutics
4d ago
MNMD
Psychedelic: Bright Minds reports results from Phase 2 BMB-101 trial
PremiumThe FlyPsychedelic: Bright Minds reports results from Phase 2 BMB-101 trial
8d ago
CMPS
DRUG
Needham names Mind Medicine top pick, adds to Conviction List
Premium
The Fly
Needham names Mind Medicine top pick, adds to Conviction List
11d ago
MNMD
Ametek, MindMed, Atai, Prime and KB Home Trending
Premium
Weekend Updates
Ametek, MindMed, Atai, Prime and KB Home Trending
20d ago
AME
KBH
MindMed Expands Into Autism: What Investors Should Know About the New MM402 Trial
PremiumCompany Announcements
MindMed Expands Into Autism: What Investors Should Know About the New MM402 Trial
21d ago
MNMD
Midday Fly By: Wegovy weight loss pill approved, ServiceNow inks security deal
PremiumThe Fly
Midday Fly By: Wegovy weight loss pill approved, ServiceNow inks security deal
24d ago
KR
AME
Coty downgraded, Spruce Biosciences initiated: Wall Street’s top analyst calls
PremiumThe Fly
Coty downgraded, Spruce Biosciences initiated: Wall Street’s top analyst calls
24d ago
BC
AME
Video: HII sails higher as President unveils plans for ‘Trump-class’ battleships
PremiumThe Fly
Video: HII sails higher as President unveils plans for ‘Trump-class’ battleships
24d ago
HII
NVO
Mind Medicine initiated with a Buy at JonesResearch
PremiumThe FlyMind Medicine initiated with a Buy at JonesResearch
24d ago
MNMD
Psychedelic: Atai Beckley, Cybin report quarterly earnings
Premium
The Fly
Psychedelic: Atai Beckley, Cybin report quarterly earnings
2M ago
PBM
ABBV
MindMed’s Earnings Call: Positive Outlook Amid Financial Challenges
Premium
Company Announcements
MindMed’s Earnings Call: Positive Outlook Amid Financial Challenges
2M ago
MNMD
Mind Medicine’s Strong Financial Position and Clinical Progress Drive Buy Rating
PremiumRatings
Mind Medicine’s Strong Financial Position and Clinical Progress Drive Buy Rating
2M ago
MNMD
Mind Medicine’s Promising Clinical Progress and Strategic Advancements Justify Buy Rating
PremiumRatings
Mind Medicine’s Promising Clinical Progress and Strategic Advancements Justify Buy Rating
2M ago
MNMD
Mind Medicine price target raised to $25 from $16 at Canaccord
PremiumThe Fly
Mind Medicine price target raised to $25 from $16 at Canaccord
2M ago
MNMD
Mind Medicine’s Accelerated Phase 3 Trials and Strong Financial Position Signal Promising Future
PremiumRatings
Mind Medicine’s Accelerated Phase 3 Trials and Strong Financial Position Signal Promising Future
2M ago
MNMD
MindMed Reports Q3 2025 Financial Progress
PremiumCompany AnnouncementsMindMed Reports Q3 2025 Financial Progress
2M ago
MNMD
Mind Medicine Reports Q3 2025 Financial Results
Premium
Company Announcements
Mind Medicine Reports Q3 2025 Financial Results
2M ago
8K
MNMD
Mind Medicine reports Q3 EPS (78c), consensus (50c)
Premium
The Fly
Mind Medicine reports Q3 EPS (78c), consensus (50c)
2M ago
MNMD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >